Bicocca Open Archive

Logo unimib boa
CORTINOVIS, DIEGO LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 9.492
NA - Nord America 8.977
EU - Europa 5.365
SA - Sud America 1.392
AF - Africa 123
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 6
Totale 25.362
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.749
SG - Singapore 3.351
CN - Cina 1.962
HK - Hong Kong 1.691
VN - Vietnam 1.489
RU - Federazione Russa 1.280
BR - Brasile 1.131
IT - Italia 1.103
DE - Germania 704
IE - Irlanda 687
SE - Svezia 504
KR - Corea 291
GB - Regno Unito 232
UA - Ucraina 193
ID - Indonesia 163
FI - Finlandia 133
AT - Austria 131
CA - Canada 130
IN - India 128
AR - Argentina 117
FR - Francia 91
NL - Olanda 87
BD - Bangladesh 76
MX - Messico 72
JP - Giappone 68
ZA - Sudafrica 58
PL - Polonia 56
TR - Turchia 55
IQ - Iraq 46
EC - Ecuador 44
DK - Danimarca 38
CO - Colombia 32
ES - Italia 30
BE - Belgio 25
PK - Pakistan 20
PY - Paraguay 20
SA - Arabia Saudita 18
UZ - Uzbekistan 17
MA - Marocco 16
JO - Giordania 14
VE - Venezuela 14
AE - Emirati Arabi Uniti 12
CL - Cile 12
KE - Kenya 12
AL - Albania 11
NP - Nepal 11
CZ - Repubblica Ceca 10
PE - Perù 10
EG - Egitto 9
KZ - Kazakistan 9
MY - Malesia 8
TN - Tunisia 8
TW - Taiwan 8
UY - Uruguay 8
GR - Grecia 7
IR - Iran 7
PS - Palestinian Territory 7
BG - Bulgaria 6
DO - Repubblica Dominicana 6
AZ - Azerbaigian 5
CH - Svizzera 5
DZ - Algeria 5
IL - Israele 5
LB - Libano 5
AU - Australia 4
BO - Bolivia 4
EU - Europa 4
JM - Giamaica 4
LT - Lituania 4
TT - Trinidad e Tobago 4
HU - Ungheria 3
KH - Cambogia 3
PA - Panama 3
PH - Filippine 3
RO - Romania 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BH - Bahrain 2
CY - Cipro 2
ET - Etiopia 2
GA - Gabon 2
HR - Croazia 2
KG - Kirghizistan 2
KW - Kuwait 2
LK - Sri Lanka 2
LU - Lussemburgo 2
MD - Moldavia 2
MK - Macedonia 2
MT - Malta 2
MU - Mauritius 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
SC - Seychelles 2
SI - Slovenia 2
SN - Senegal 2
Totale 25.343
Salva come PNG Salva come JPEG
Città #
Singapore 1.979
Hong Kong 1.677
Ann Arbor 1.270
Ashburn 886
Dublin 666
Hefei 632
Fairfield 533
Ho Chi Minh City 495
Woodbridge 412
Hanoi 390
Frankfurt am Main 384
Chandler 360
New York 345
Wilmington 312
Milan 310
Seoul 277
Houston 246
Santa Clara 225
Seattle 224
Beijing 215
Dallas 209
Los Angeles 209
Cambridge 208
Jacksonville 168
The Dalles 151
Princeton 146
Jakarta 141
Moscow 129
São Paulo 129
Dearborn 125
Buffalo 118
Chicago 114
Shanghai 94
Vienna 93
London 74
Lawrence 66
Nuremberg 65
Boardman 61
Munich 61
Altamura 57
Guangzhou 53
Helsinki 53
Turin 52
Nanjing 50
Rome 49
Tokyo 48
Haiphong 46
San Diego 45
Warsaw 41
Da Nang 40
Salt Lake City 39
Brooklyn 36
Council Bluffs 35
Toronto 34
Lappeenranta 33
Rio de Janeiro 33
Ha Long 32
Hải Dương 28
Kent 28
Montreal 28
Poplar 28
Johannesburg 27
Orem 27
Biên Hòa 26
Andover 25
Brussels 25
Lachine 25
Stockholm 25
San Jose 24
Amsterdam 22
Atlanta 22
Phoenix 22
Quận Bình Thạnh 22
Tianjin 22
Chennai 21
San Francisco 21
Tampa 21
Jinan 20
Mexico City 20
Ninh Bình 20
Turku 20
Can Tho 19
Dhaka 19
Belo Horizonte 18
Changsha 18
Denver 18
Baghdad 17
Elk Grove Village 17
Monza 17
Thái Nguyên 17
Boston 16
Columbus 16
Florence 16
Genoa 16
Hangzhou 16
Ottawa 16
Porto Alegre 16
Tashkent 16
Guayaquil 15
Hebei 15
Totale 15.862
Salva come PNG Salva come JPEG
Nome #
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma 434
The ‘Liaisons dangereuses’ Between Lung Cancer and Interstitial Lung Diseases: A Focus on Acute Exacerbation 418
Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment? 371
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 347
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 329
Indicators of guideline-concordant care in lung cancer defined with a modified Delphi method and piloted in a cohort of over 5,800 cases 318
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 316
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 296
Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve 276
The "digital biopsy" in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT 262
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 261
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin 255
Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis 255
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer 249
C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool 245
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 245
The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience 243
Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion 241
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 241
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients 240
Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNoms study 239
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer 238
Metabolic parameters as biomarkers of response to immunotherapy and prognosis in non-small cell lung cancer (Nsclc): A real world experience 232
Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients 229
The Association between Vitamin D and Gut Microbiota: A Systematic Review of Human Studies 229
Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy 226
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 222
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 218
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 214
Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study 213
When progressive dysphagia could be related to an “old friend” – a case report 208
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study 204
Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study. 204
RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer 203
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin 202
Vitamin D supplementation and cancer mortality: Narrative review of observational studies and clinical trials 201
The significance of dorsal sural nerve recordings in early detecting oxaliplatin-induced peripheral neuropathy. 200
Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial 200
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 198
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients 195
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 194
Clinical treatment of cholangiocarcinoma: an updated comprehensive review 193
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 190
Long-term course of oxaliplatin-induced polyneuropathy: a prospective two-year follow-up study 188
Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung Cancer 186
MR309/E-52862, a first-in-class sigma-1 receptor antagonist, in oxaliplatin-induced peripheral neuropathy. An exploratory Phase II clinical trial 185
Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis 183
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis 182
Novel cytotoxic chemotherapies in small cell lung carcinoma 177
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 176
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 176
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 167
Economic assessment of NGS testing workflow for NSCLC in a healthcare setting 163
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients 162
Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer 160
Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review 159
Focus on nivolumab in NSCLC 158
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab 155
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 152
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial 151
Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift 149
Pleural mesothelioma in situ: A comprehensive review 146
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study 146
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 143
Sneaky Diagnosis of Pleural Malignant Mesothelioma in Thoracic Surgery: All That Glitters Is Not Gold 142
Anti PD-L1 antibody: is there a histologic-oriented efficacy? Focus on atezolizumab in squamous cell non-small cell lung cancer 140
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients 138
ALK determination: Liquid and tissue biopsy. Comparing techniques and effectiveness of alectinib in a controversial clinical case [Determinazione di ALK: Tra biopsia liquida e tissutale. Tecniche a confronto ed efficacia di alectinib in un caso clinico controverso] 135
Abstract 987: Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 135
Colorectal Cancer Pulmonary Metastasectomy: When, Why and How 134
Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer 134
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial 133
Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres 132
Harnessing DLL3 inhibition: From old promises to new therapeutic horizons 132
Novel Therapeutic Options for Small Cell Lung Cancer 131
VITAMIN D SUPPLEMENTATION MAY IMPROVE COVID-19 PROGNOSIS? EVIDENCE FROM A SYSTEMATIC REVIEW AND META-ANALYSIS 130
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma 129
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 128
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer 125
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer 118
Time to Next Treatment Following Sub-Ablative Progression Directed Radiation Therapy for Oligoprogressive Non-Small-Cell Lung Cancer 117
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer 117
A new race against lung cancer 114
Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives 112
Oxaliplatin doublets in non-small cell lung cancer: A literature review 112
The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer 111
Intratumoral Treatment in Lung Cancer: Is It Time to Move Towards Clinical Practice? 111
Treatment patterns, clinical outcomes and healthcare costs of advanced non-small cell lung cancer: A real-world evaluation in Italy 111
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04–2016 111
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer 110
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? 109
Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review 109
MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database 108
Targeted therapies and immunotherapy in non-small-cell lung cancer 108
Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: Analysis of 318 patients 108
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer 107
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 106
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO) 104
Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges 103
Newest therapeutic strategies impacting on rarest thoracic malignancies: The clinical case report of biphasic pleural mesothelioma 101
Totale 18.463
Salva come PNG Salva come JPEG
Categoria #
all - tutte 97.186
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 97.186
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021896 0 0 0 0 0 0 152 178 142 155 126 143
2021/20221.108 102 144 159 114 64 77 50 42 55 58 82 161
2022/20231.743 211 504 138 184 112 244 24 117 113 39 43 14
2023/20242.515 45 44 45 64 588 530 444 77 309 57 47 265
2024/20256.752 312 712 289 252 541 217 537 207 656 999 657 1.373
2025/20269.688 2.236 1.681 1.247 1.748 1.810 891 75 0 0 0 0 0
Totale 26.290